Navigation Links
Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
Date:7/23/2012

CAMBRIDGE, Mass., July 23, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

Having completed enrollment of a 150-patient randomized Phase 2 study in advanced non-small cell lung cancer, Cerulean is beginning to capitalize on the breadth of the CRLX101 opportunity by expanding its development into additional tumor types with several studies conducted by leading investigators.  This newly opened trial is designed to evaluate the activity of CRLX101, a nanopharmaceutical that inhibits both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in ovarian cancer patients whose disease has progressed following standard first-line platinum-based therapy.  Current approved second-line therapy for ovarian cancer includes use of the topoisomerase 1 inhibitor, topotecan, which has limitations.  The study is being conducted at the Massachusetts General Hospital and led by principal investigator Carolyn Krasner, M.D., in cooperation with the Dana Farber Cancer Institute, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center.  

"Not only do women with advanced stage ovarian cancer have limited treatment options, but they also suffer from many disease-related symptoms and treatment-related side effects," said Dr. Krasner.  "This study will enable us to evaluate the potential use of CRLX101 as a treatment option for those patients." 

"This trial is intended to build on our current clinical data and determine if CRLX101 can offer ovarian cancer patients a new treatment option," said Edward Garmey, M.D., chief medical officer of Cerulean.  "We are excited to partner with Dr. Krasner and to expand the development strategy of CRLX101 in an indication with such high unmet needs."

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha.  CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors, prolonging drug exposure at the site of action.  Significant anti-tumor activity has been observed across a wide range of cancers in animal models.  CRLX101 is currently in Phase 2 clinical development.  More information on CRLX101 clinical studies can be found at www.clinicaltrials.gov.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals.  Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs.  With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs.  Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC.  Cerulean is located in Cambridge, Massachusetts.  For more information, please visit the Company's website at http://www.ceruleanrx.com.

Media Contacts:
Schwartz MSL
Benjamin Navon/Kathy Vigneault
cerulean@schwartzmsl.com
+1 781-684-0770


'/>"/>
SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
2. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
3. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
4. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
5. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. China Health Resource Announces Go Global Initiative For New Product Introductions
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
9. Ampio Pharmaceuticals Announces Closing of Public Offering
10. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
11. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
Breaking Medicine News(10 mins):